🇺🇸 FDA
Patent

US 7964359

Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance

granted A61KA61K38/28

Quick answer

US patent 7964359 (Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance) held by Acumen Pharmaceuticals, Inc. expires Mon Jun 16 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Acumen Pharmaceuticals, Inc.
Grant date
Tue Jun 21 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 16 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K38/28